Drugs / CDC-801
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00006097 | Aug 1999 → Jul 2005 | leukemia | Boston Medical Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00045786 | Oct → Dec 2001 | myelodysplastic syndrome | Celgene Corporation | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CDC-801 | ChEMBL registry synonym — accepted as the source's own label CHEMBL88153 ↗ |
| Known as | CC-1088 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00045786 ↗ |
| Modality | Small molecule | — CHEMBL88153 ↗ |
| Route | Oral | “Patients receive oral CC-1088 three times a day for 28 days.” NCT00006097 ↗ |